BR100 Decreased By (-0.07%)
BR30 Decreased By (-1.13%)
KSE100 Increased By (0.09%)
KSE30 Decreased By (-0.05%)
AGHA 6.03 Decreased By ▼ -0.02 (-0.33%)
BECO 3.83 No Change ▼ 0.00 (0%)
BML 56.40 Decreased By ▼ -1.93 (-3.31%)
BOP 28.07 Decreased By ▼ -0.28 (-0.99%)
CNERGY 12.28 Decreased By ▼ -1.36 (-9.97%)
CSIL 5.34 Increased By ▲ 0.13 (2.5%)
FCCL 53.85 Increased By ▲ 1.57 (3%)
FFL 12.79 Decreased By ▼ -0.11 (-0.85%)
FNEL 1.12 Decreased By ▼ -0.01 (-0.88%)
KEL 5.64 Decreased By ▼ -0.15 (-2.59%)
KOSM 5.38 Decreased By ▼ -0.13 (-2.36%)
LOTCHEM 23.60 Decreased By ▼ -0.29 (-1.21%)
MLCF 92.03 Increased By ▲ 1.52 (1.68%)
NBP 162.30 Increased By ▲ 2.58 (1.62%)
NCPL 48.79 Decreased By ▼ -0.81 (-1.63%)
NPL 50.50 Decreased By ▼ -1.30 (-2.51%)
OGDC 302.42 Decreased By ▼ -4.36 (-1.42%)
PACE 9.14 Decreased By ▼ -0.01 (-0.11%)
PAEL 31.75 Decreased By ▼ -0.58 (-1.79%)
PIBTL 12.80 Decreased By ▼ -0.13 (-1.01%)
PPL 211.50 Decreased By ▼ -2.43 (-1.14%)
PRL 87.26 Decreased By ▼ -9.70 (-10%)
PTC 43.99 Decreased By ▼ -1.20 (-2.66%)
SSGC 22.77 Increased By ▲ 0.24 (1.07%)
TBL 8.90 Decreased By ▼ -0.12 (-1.33%)
TELE 6.49 Decreased By ▼ -0.23 (-3.42%)
TPL 24.10 Decreased By ▼ -1.81 (-6.99%)
TPLP 12.15 Decreased By ▼ -0.45 (-3.57%)
TREET 23.50 Increased By ▲ 0.04 (0.17%)
TRG 51.75 Decreased By ▼ -0.21 (-0.4%)
World

Moderna seeks full US approval for Covid-19 shot

  • More than 124 million doses of the vaccine have been administered in the US.
Published Updated
By

WASHINGTON: Moderna said Tuesday it was applying for full approval in the United States of its Covid-19 vaccine for people aged 18 and over, joining Pfizer which made the same request last month.

The vaccine has been available since December 18, 2020 under an "emergency use authorization" intended to make life-saving medications available as fast as possible.

More than 124 million doses of the vaccine have been administered in the US.

"We are pleased to announce this important step in the US regulatory process for a Biologics License Application (BLA) of our COVID-19 vaccine," said Stephane Bancel, the company's CEO.

"We look forward to working with the FDA and will continue to submit data from our Phase 3 study and complete the rolling submission."

Last week Moderna announced its vaccine was highly effective in adolescents and it would seek authorization among 12-to-17-year-olds soon.

The two-shot regime is around 90 percent effective against symptomatic Covid-19 and 95 percent effective against severe disease.

Comments

Comments are closed for this article.